Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio lung oncology group study 001 (KLOG001)

Masayoshi Miyawaki, Katsuhiko Naoki, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Takashi Sato, Shinnosuke Ikemura, Keiko Ohgino, Kota Ishioka, Daisuke Arai, Ho Namkoong, Kengo Otsuka, Masaki Miyazaki, Tetsuo Tani, Aoi Kuroda, Makoto Nishino, Hiroyuki Yasuda, Ichiro Kawada, Hidefumi Koh, Morio NakamuraTakeshi Terashima, Fumio Sakamaki, Koichi Sayama, Tomoko Betsuyaku, Kenzo Soejima

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio lung oncology group study 001 (KLOG001)'. Together they form a unique fingerprint.

Medicine & Life Sciences